ImmuCell Corporation (ICCC): Price and Financial Metrics
ICCC Price/Volume Stats
| Current price | $5.24 | 52-week high | $8.60 |
| Prev. close | $5.34 | 52-week low | $4.26 |
| Day low | $5.14 | Volume | 18,400 |
| Day high | $5.24 | Avg. volume | 10,865 |
| 50-day MA | $5.05 | Dividend yield | N/A |
| 200-day MA | $5.60 | Market Cap | 40.59M |
ICCC Stock Price Chart Interactive Chart >
ICCC Stock Summary
- With a one year PEG ratio of 0.32, IMMUCELL CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.56% of US stocks.
- Over the past twelve months, ICCC has reported earnings growth of -2,209.43%, putting it ahead of just 0.65% of US stocks in our set.
- As for revenue growth, note that ICCC's revenue has grown -23.31% over the past 12 months; that beats the revenue growth of merely 11.12% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to IMMUCELL CORP, a group of peers worth examining would be ICPT, HYPR, XBIO, MX, and SPOK.
- Visit ICCC's SEC page to see the company's official filings. To visit the company's web site, go to immucell.com.
ICCC Valuation Summary
- In comparison to the median Healthcare stock, ICCC's price/sales ratio is 42.11% higher, now standing at 2.7.
- Over the past 243 months, ICCC's price/sales ratio has gone up 1.
Below are key valuation metrics over time for ICCC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ICCC | 2023-09-22 | 2.7 | 1.6 | -7.0 | -9.3 |
| ICCC | 2023-09-21 | 2.6 | 1.5 | -6.7 | -9.0 |
| ICCC | 2023-09-20 | 2.6 | 1.5 | -6.8 | -9.0 |
| ICCC | 2023-09-19 | 2.6 | 1.5 | -6.8 | -9.1 |
| ICCC | 2023-09-18 | 2.6 | 1.5 | -6.8 | -9.1 |
| ICCC | 2023-09-15 | 2.6 | 1.5 | -6.9 | -9.2 |
ICCC Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 156.17%.
- Its year over year price growth rate is now at -15.31%.
- Its 4 year net cashflow from operations growth rate is now at -59.23%.
The table below shows ICCC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 20.45507 | 1.858877 | 0.051037 |
| 2022-06-30 | 20.45507 | 1.858877 | 0.273416 |
| 2022-03-31 | 21.13551 | 2.216251 | 1.098677 |
| 2021-12-31 | 19.24297 | 0.95417 | -0.078292 |
| 2021-09-30 | 17.54247 | 0.522525 | 0.036404 |
| 2021-06-30 | 16.11482 | -0.403793 | -0.434248 |
ICCC Price Target
For more insight on analysts targets of ICCC, see our ICCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ImmuCell Corporation (ICCC) Company Bio
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.
Latest ICCC News From Around the Web
Below are the latest news stories about IMMUCELL CORP that investors may wish to consider to help them evaluate ICCC as an investment opportunity.
ImmuCell Announces Submission of CMC Technical Section to the FDAPORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA. On August 10, 2023, the Company issued a disclosure stating that |
Q2 2023 ImmuCell Corp Earnings CallQ2 2023 ImmuCell Corp Earnings Call |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023. Management’s Discussion: “Our unaudited, preliminary product sales were first reported on July 11, 2023,” comment |
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ETPORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023PORTLAND, Maine, July 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023. Preliminary, Unaudited Total Sales Results: 20232022($ Decrease) (% Decrease)During th |
ICCC Price Returns
| 1-mo | 14.91% |
| 3-mo | N/A |
| 6-mo | 5.86% |
| 1-year | -29.95% |
| 3-year | -4.20% |
| 5-year | -36.41% |
| YTD | -14.10% |
| 2022 | -23.75% |
| 2021 | 34.46% |
| 2020 | 15.53% |
| 2019 | -26.95% |
| 2018 | -19.80% |
Continue Researching ICCC
Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...